Phase 1 Glaucoma Trial, Recruiting NCT07036510 Sponsor: EyeD Pharma Condition: Glaucoma
Back to Glaucoma

Phase 1 Glaucoma Trial, Recruiting

NCT07036510
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give their consent to participate after being fully informed about the trial.
  • People who are in good general and mental health, without any ongoing significant medical concerns in their medical history.
  • People who have been diagnosed with open-angle glaucoma or high eye pressure (ocular hypertension), and also have an age-related cataract that is suitable for a standard lens implant during cataract surgery.
  • People who have had a successful cataract surgery without complications.

Who may not be able to join:

  • People who have a history of allergic reactions or medical reasons preventing them from taking beta-blocker medications (a type of drug used to treat conditions like glaucoma and high blood pressure).
  • People who are currently using any medication — whether taken by mouth or applied to the eye — that is known to affect vision, pupil size, or the structure of the iris (the coloured part of the eye).
  • People for whom stopping their current eye pressure-lowering medications would carry significant health risks.
  • People who have other significant eye conditions beyond high eye pressure, glaucoma, or cataracts.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +3242299000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
EyeD Pharma
Registry
ClinicalTrials.gov
Start date
12 June 2025
Est. completion
1 January 2027

Where this trial is recruiting

Panama

Primary endpoints

Number (%) of participants experiencing adverse events; Number (%) of participants experiencing adverse events of special interest (AESI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov